Omar Alghazo

The application of theranostics in different stages of prostate cancer

Omar Alghazo, Renu Eapen, Samantha Koschel, Marcus Cumberbatch, James Buteau, Rebecca Loh, Nathan Lawrentschuk, Declan G Murphy

Journal article  |  2021  |  FUTURE ONCOLOGY

Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is..

Is the Toxicity of Salvage Prostatectomy Related to the Primary Prostate Cancer Therapy Received?

Luis Ribeiro, Thomas Stonier, Luke Stroman, Rafael Tourinho-Barbosa, Omar Alghazo, Mathias Winkler, Prokar Dasgupta, Rick Popert, Xavier Cathelineau, Rafael Sanchez-Salas, Declan G Murphy, Mark Emberton, Paul Cathcart

Journal article  |  2021  |  JOURNAL OF UROLOGY

PURPOSE: To compare the toxicity profile and oncological outcome of salvage radical prostatectomy following focal therapy versus s..

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of Lu-177-PSMA-617 Prior to Prostatectomy

Nattakorn Dhiantravan, John Violet, Renu Eapen, Omar Alghazo, Mark Scalzo, Price Jackson, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Sandhu, Scott G Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Journal article  |  2021  |  EUROPEAN UROLOGY FOCUS

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium..

Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).

Omar Alghazo, Renu Eapen, Nattakorn Dhiantravan, John A Violet, Price Jackson, Mark Scalzo, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Kaur Sandhu, Scott Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

TPS264 Background: High-risk localised prostate cancer (HRCaP) is treated by radical prostatectomy (RP) or radiotherapy. Despite ..

Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on F-18-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer EDITORIAL COMMENT

Omar Alghazo, Marcus Cumberbatch, Declan G Murphy

Journal article  |  2020  |  JOURNAL OF UROLOGY

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

Niranjan J Sathianathen, Samantha Koschel, Isaac A Thangasamy, Jiasian Teh, Omar Alghazo, Georgiana Butcher, Harriet Howard, Jada Kapoor, Nathan Lawrentschuk, Shankar Siva, Arun Azad, Ben Tran, Damien Bolton, Declan G Murphy

Journal article  |  2020  |  EUROPEAN UROLOGY

CONTEXT: There have been substantial changes in the management of men with metastatic hormone-sensitive prostate cancer (mHSPC) ov..

Less, not More, Antibiotics Please

Declan G Murphy, Omar Alghazo, Claire Pascoe, Nathan Lawrentschuk

Journal article  |  2020  |  EUROPEAN UROLOGY FOCUS

Navigating systemic therapy for metastatic castration-naive prostate cancer

EM Kwan, IA Thangasamy, J Teh, O Alghazo, NJ Sathianathen, N Lawrentschuk, AA Azad

Journal article  |  2020  |  WORLD JOURNAL OF UROLOGY

INTRODUCTION: The last decade has seen a remarkable shift in the treatment landscape of advanced prostate cancer, none more so tha..

Re: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer

Daniel McLennan, Niranjan Sathianathen, Omar Alghazo, Arun Azad, Declan G Murphy

Journal article  |  2020  |  EUROPEAN UROLOGY

Novel agents for metastatic hormone-sensitive prostate cancer - a practice guide for urologists

Isaac A Thangasamy, Edmond M Kwan, Jiasian Teh, Niranjan Sathianathen, Omar Alghazo, Shankar Siva, Arun Azad, Declan G Murphy

Journal article  |  2019  |  BJU INTERNATIONAL

The last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC)..